Bluejay Diagnostics financials
$0.9390−2.18%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $249.0K | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $48.9K | $0.00 |
| Gross margin | — | — | — | 19.6% | — |
| Operating income | -$7.0M | -$7.2M | -$10.3M | -$9.6M | -$3.2M |
| Net income | -$6.8M | -$20.9M | -$10.0M | -$9.3M | -$3.5M |
| Net margin | — | — | — | −3733.1% | — |
| Diluted EPS | $-15.25 | $-456.75 | $-14525.92 | $-14752.00 | $-13120.00 |
| EBITDA | -$6.9M | -$7.1M | -$9.7M | -$9.2M | -$3.1M |
| Operating cash flow | -$6.1M | -$7.8M | -$8.3M | -$7.7M | -$4.4M |
| Free cash flow | -$6.2M | -$8.1M | -$9.0M | -$8.9M | -$4.4M |
| Diluted shares | 0.4M | 0.0M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $5.2M | $4.3M | $2.2M | $10.1M | $19.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $7.1M | $6.7M | $4.9M | $13.5M | $21.0M |
| Total liabilities | $1.1M | $927.9K | $2.0M | $2.0M | $637.2K |
| Shareholders' equity | $6.0M | $5.7M | $2.9M | $11.5M | $20.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology